

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

## **Glimepiride Tablets IP**

### **Amaryl® 1mg/2mg/3mg**

#### **Abridged Prescribing Information**

#### **COMPOSITION**

Tablets with 1mg, 2mg, 3mg glimepiride. Oral antidiabetic agent of the sulphonylurea group.

#### **THERAPEUTIC INDICATION**

Non-insulin dependent (type 2) diabetes mellitus, whenever blood sugar levels cannot be controlled adequately by diet, physical exercise or weight reduction alone. Amaryl® is not suitable for insulin-dependent (type 1) diabetes mellitus, diabetic ketoacidosis; diabetic precoma or coma. Amaryl® may be combined with other non-betacytotropic oral anti-diabetic agents and may also be used with insulin.

#### **DOSAGE AND ADMINISTRATION**

Dosage is governed by desired blood glucose level. Dosage must be lowest which is sufficient to achieve the desired metabolic control. Regularly measure glucose levels in blood and urine. Mistakes like forgetting dose should not be corrected by subsequently taking larger dose. Usual initial dose is 1mg once daily, usual daily dose is 1mg to 4mg in well-controlled patients. Daily dose of more than 6mg are more effective only in minority of patients. Not recommended in children.

#### **SAFETY-RELATED INFORMATION**

**Contraindications :** Hypersensitivity to glimepiride or other sulphonylureas or sulphonamides or any of its excipients; pregnant women; breast feeding women. No experience gained in patients with severe impairment of liver function and in dialysis patient.

**Warnings:** Temporary changeover to insulin may be necessary in exceptional stress situations (e.g., trauma, surgery, febrile infections).

**Precautions :** Risk of hypoglycemia may be increased in initial weeks of treatment. Hypoglycemia may be controlled by intake of carbohydrates. Symptoms of hypoglycemia may be milder or absent in elderly patients and where there is autonomic neuropathy or patients receiving concurrent treatment with beta blockers, clonidine, reserpine, guanethidine or other sympatholytic drugs. Severe hypoglycemia requires immediate treatment. Treatment of patients with G6PD deficiency with sulphonylurea agents can lead to haemolytic anemia. Non-sulfonyl urea alternative should be considered.

**Pregnancy and Lactation :** Contraindicated.

**Adverse Reactions :** Hypoglycemia may occur and may also be prolonged; temporary visual impairment; gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain, sensation of fullness in epigastrium, diarrhoea) may occur; hepatitis, elevation of liver enzymes, cholestasis and jaundice may occur; change in blood picture may occur; allergic reactions or pseudo allergic reactions may occur occasionally. Like all sulphonylureas, it can cause weight gain.

For full prescribing information, refer to the company website [www.sanofi.in](http://www.sanofi.in)

**Updated : Jan 2026**

**Source : CCDS Version 14 dated 12<sup>th</sup> May 2016**